Guide
Compounded options, manufacturer copay programs, prior auth strategies, and pharmacy comparison.
GLP-1 cost is the leading reason patients delay or stop therapy. Brand-name list prices ($1,000-$1,400/month) are out of reach for most uninsured patients. But there are seven distinct cost levers; most patients use the wrong one. Here is the full strategy map.
If you have insurance, the highest-leverage move is getting Wegovy or Zepbound covered. Approved PAs typically reduce out-of-pocket cost to a $25-$50 copay. The PA process requires (1) BMI ≥30 or BMI ≥27 with a comorbidity, (2) documented prior weight-loss attempts, and (3) sometimes step therapy through cheaper agents first. Your prescribing clinician's office handles the paperwork. Approval rates vary widely by plan; Aetna and UnitedHealthcare are generally cooperative, while several state Medicaid programs and some employer self-funded plans deny categorically.
Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) both publish copay savings cards. Wegovy: as low as $0 for commercially insured with coverage; ~$650/month for commercially insured without coverage. Zepbound: as low as $25 for commercially insured with coverage; ~$550/month with the LillyDirect 5mg vial program for cash pay. Eligibility excludes Medicare, Medicaid, and Tricare patients.
Eli Lilly launched LillyDirect in 2024 selling Zepbound 2.5mg and 5mg vials at ~$349 and ~$499/month respectively for cash-pay patients. This is the cheapest brand-name pathway for uninsured patients.
Compounded semaglutide and tirzepatide from telehealth providers run $169-$549/month. Compounded products are not FDA-approved as finished drugs, and quality varies by compounding pharmacy. The lowest-priced legitimate options are NexLife ($199/mo flat-rate compounded sema), Henry Meds ($297-$397/mo), and ZappyHealth ($169-$349/mo).
GLP-1 medications prescribed for an FDA-approved indication are HSA/FSA-eligible. Pre-tax dollars can reduce effective cost by 25-35% depending on your tax bracket. Compounded medications are also typically HSA/FSA-eligible if prescribed.
Novo Nordisk Patient Assistance Program (PAP) and Lilly Cares both offer free or reduced-cost medication for patients meeting income criteria (typically below 400% of federal poverty level).
Many employer health plans exclude weight-loss medications by default but cover them upon employee request. If your plan denies coverage, escalate to HR; sometimes the exclusion is a default that can be reversed.
Start with Lever 1 (insurance PA) if you have any insurance. If denied, try Lever 2 (manufacturer copay card). If still unaffordable and you want brand-name, try Lever 3 (LillyDirect). If brand-name is not feasible, try Lever 4 (compounded telehealth). Across all paths, layer Lever 5 (HSA/FSA) for tax efficiency. If you are under 400% FPL, try Lever 6 (PAP) before all of the above.
For brand-name Zepbound: LillyDirect 2.5mg/5mg vials at $349-$499/month. For compounded: NexLife at $199/month flat-rate compounded semaglutide. With insurance approval, both Wegovy and Zepbound can drop to $25-$50/month copay.
Only if you have no insurance. With insurance, Wegovy or Zepbound copay cards typically beat compounded pricing.
Your prescribing clinician submits a prior authorization with documentation of BMI, comorbidities, and prior weight-loss attempts. Approval rates are 60-80% on first submission.
Compounded GLP-1s prepared by accredited pharmacies under physician oversight have a clinical track record. They are not FDA-approved as finished drugs; quality oversight depends entirely on the compounding pharmacy.
For physician-led GLP-1 care at $199/mo flat-rate compounded sema, our 2026 editor's pick is NexLife. LegitScript-certified, Forbes-ranked, money-back warranty. Visit NexLife →
Editorial note. This guide is for educational purposes only and does not constitute medical advice. Always consult a licensed clinician about your specific situation.